TTOO (T2 Biosystems) Long-Term Capital Lease Obligation : $5.30 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is T2 Biosystems Long-Term Capital Lease Obligation?

T2 Biosystems's Long-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $5.30 Mil.

T2 Biosystems's quarterly Long-Term Capital Lease Obligation declined from Mar. 2024 ($6.18 Mil) to Jun. 2024 ($5.75 Mil) and declined from Jun. 2024 ($5.75 Mil) to Sep. 2024 ($5.30 Mil).

T2 Biosystems's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($9.36 Mil) to Dec. 2022 ($8.21 Mil) and declined from Dec. 2022 ($8.21 Mil) to Dec. 2023 ($6.60 Mil).

T2 Biosystems Long-Term Capital Lease Obligation Historical Data

The historical data trend for T2 Biosystems's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

T2 Biosystems Long-Term Capital Lease Obligation Chart

T2 Biosystems Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.87

10.53

9.36

8.21

6.60

T2 Biosystems Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															7.02	6.60	6.18	5.75	5.30

T2 Biosystems (OTCPK:TTOO) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

T2 Biosystems Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of T2 Biosystems's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

T2 Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » T2 Biosystems Inc (OTCPK:TTOO) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

3T2:Germany

Address

101 Hartwell Avenue, Lexington, MA, USA, 02421

Website

https://www.t2biosystems.com

T2 Biosystems Inc is a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes. It is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. The company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the proprietary T2 Magnetic Resonance technology.

Executives

David B Elsbree	director	C/O ACME PACKET, INC., 100 CROSBY DRIVE, BEDFORD MA 01730
Cr Group L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Unlev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii (cayman) Lev Aiv I L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund B (cayman) L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii - Parallel Fund (a) L.p.	10 percent owner	C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Crg Partners Iii L.p.	10 percent owner	1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Michael Terrence Gibbs	officer: General Counsel	12 STONEY BROOK RD., HOPKINTON MA 01748
John M Sprague	officer: Chief Financial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Sperzel John J Iii	director, officer: See Remarks	61 CRESTVIEW LANE, BRUNSWICK ME 04011
Brett A. Giffin	officer: Chief Commercial Officer	101 HARTWELL AVE., LEXINGTON MA 02421
Alec Barclay	officer: SVP, Operations	101 HARTWELL AVE., LEXINGTON MA 02421
Aparna Ahuja	officer: Chief Medical Officer	101 HARTWELL AVENUE, LEXINGTON MA 02421
Laura Lee Adams	director	101 HARTWELL AVE., LEXINGTON MA 02421
Anthony Pare	officer: Chief Commercial Officer	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184